HRP20120350T1 - Novi oblici cddo metilnog estera - Google Patents
Novi oblici cddo metilnog estera Download PDFInfo
- Publication number
- HRP20120350T1 HRP20120350T1 HRP20120350AT HRP20120350T HRP20120350T1 HR P20120350 T1 HRP20120350 T1 HR P20120350T1 HR P20120350A T HRP20120350A T HR P20120350AT HR P20120350 T HRP20120350 T HR P20120350T HR P20120350 T1 HRP20120350 T1 HR P20120350T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- methyl ester
- cddo
- excipient
- glassy
- Prior art date
Links
- WPTTVJLTNAWYAO-KPOXMGGZSA-N Bardoxolone methyl Chemical compound C([C@@]12C)=C(C#N)C(=O)C(C)(C)[C@@H]1CC[C@]1(C)C2=CC(=O)[C@@H]2[C@@H]3CC(C)(C)CC[C@]3(C(=O)OC)CC[C@]21C WPTTVJLTNAWYAO-KPOXMGGZSA-N 0.000 title claims abstract 11
- 239000007787 solid Substances 0.000 claims abstract 8
- 239000000843 powder Substances 0.000 claims abstract 3
- 125000001475 halogen functional group Chemical group 0.000 claims abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims 8
- 239000012453 solvate Substances 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940041181 antineoplastic drug Drugs 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 230000009477 glass transition Effects 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- -1 organic acid salt Chemical class 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 229920005613 synthetic organic polymer Polymers 0.000 claims 2
- BXGYYDRIMBPOMN-UHFFFAOYSA-N 2-(hydroxymethoxy)ethoxymethanol Chemical compound OCOCCOCO BXGYYDRIMBPOMN-UHFFFAOYSA-N 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 150000001719 carbohydrate derivatives Chemical class 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 229920001531 copovidone Polymers 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical group O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Glass Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95593907P | 2007-08-15 | 2007-08-15 | |
PCT/US2008/009703 WO2009023232A1 (fr) | 2007-08-15 | 2008-08-14 | Nouvelles formes d'ester méthylique de cddo |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20120350T1 true HRP20120350T1 (hr) | 2012-05-31 |
Family
ID=40351005
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120350AT HRP20120350T1 (hr) | 2007-08-15 | 2012-04-18 | Novi oblici cddo metilnog estera |
HRP20161503TT HRP20161503T1 (hr) | 2007-08-15 | 2016-11-15 | Novi oblici cddo metilnog estera |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20161503TT HRP20161503T1 (hr) | 2007-08-15 | 2016-11-15 | Novi oblici cddo metilnog estera |
Country Status (29)
Country | Link |
---|---|
US (3) | US8088824B2 (fr) |
EP (2) | EP2187741B1 (fr) |
JP (4) | JP5005812B2 (fr) |
KR (2) | KR101544766B1 (fr) |
CN (2) | CN101820758B (fr) |
AR (2) | AR073155A1 (fr) |
AT (1) | ATE549035T1 (fr) |
AU (1) | AU2008287388B2 (fr) |
BR (1) | BRPI0815540A8 (fr) |
CA (2) | CA2871864C (fr) |
CL (1) | CL2008002417A1 (fr) |
CY (2) | CY1112864T1 (fr) |
DK (2) | DK2187741T3 (fr) |
EA (2) | EA023550B1 (fr) |
ES (2) | ES2602978T3 (fr) |
HK (1) | HK1143537A1 (fr) |
HR (2) | HRP20120350T1 (fr) |
HU (1) | HUE031866T2 (fr) |
IL (2) | IL203824A (fr) |
LT (1) | LT2450057T (fr) |
MX (1) | MX2010001628A (fr) |
NZ (1) | NZ583269A (fr) |
PL (2) | PL2450057T3 (fr) |
PT (2) | PT2450057T (fr) |
SG (2) | SG177905A1 (fr) |
SI (2) | SI2450057T1 (fr) |
TW (2) | TWI486357B (fr) |
WO (1) | WO2009023232A1 (fr) |
ZA (1) | ZA201001066B (fr) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
US7435755B2 (en) | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
DK1465615T3 (da) | 2002-01-15 | 2012-11-12 | Dartmouth College | Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf |
US8921340B2 (en) | 2006-11-17 | 2014-12-30 | Trustees Of Dartmouth College | Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions |
CA2670099A1 (fr) | 2006-11-17 | 2008-05-29 | Trustees Of Dartmouth College | Synthese et activites biologiques de nouveaux composes tricycliques-bis-enones (tbe) |
WO2008064132A2 (fr) | 2006-11-17 | 2008-05-29 | Trustees Of Dartmouth College | Triterpénoïdes synthétiques et bis-énones tricycliques pour une utilisation dans la stimulation de croissance osseuse et cartilagineuse |
US8088824B2 (en) * | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
CA2711834C (fr) * | 2008-01-11 | 2017-03-14 | Reata Pharmaceuticals, Inc. | Triterpenoides synthetiques et procedes d'utilisation dans le traitement de maladies |
EA019263B1 (ru) | 2008-04-18 | 2014-02-28 | Ритэ Фамэсутикл, Инк. | Антиоксидативные модуляторы воспаления: производные олеанолевой кислоты с аминовыми и другими модификациями на с-17 |
CN104250280A (zh) | 2008-04-18 | 2014-12-31 | 里亚塔医药公司 | 抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物 |
US7915402B2 (en) | 2008-04-18 | 2011-03-29 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring |
WO2009146216A2 (fr) | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals. Inc. | Modulateurs d’inflammation antioxydant : nouveaux dérivés d’acide oléanolique |
MX339476B (es) | 2008-04-18 | 2016-05-27 | Reata Pharmaceuticals Inc | Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso. |
ES2449396T3 (es) | 2008-07-22 | 2014-03-19 | Trustees Of Dartmouth College | Cianoenonas monocíclicas y métodos de uso de las mismas |
HUE035013T2 (en) * | 2009-02-13 | 2018-05-02 | Reata Pharmaceuticals Inc | Delayed oral dosage forms containing amorphous CDDO-Me |
CN102762101B (zh) | 2010-02-18 | 2014-09-17 | 高点制药有限责任公司 | 取代的稠合咪唑衍生物、药物组合物及其使用方法 |
US8759535B2 (en) | 2010-02-18 | 2014-06-24 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
MX357596B (es) | 2010-04-12 | 2018-07-16 | Reata Pharmaceuticals Inc | Método para tratar obesidad utilizando moduladores de inflamación con antioxidantes. |
CN103596929B (zh) | 2010-12-17 | 2016-10-19 | 里亚塔医药公司 | 作为抗氧化发炎调节剂的吡唑及嘧啶三环烯酮 |
ME03469B (fr) | 2011-03-11 | 2020-01-20 | Reata Pharmaceuticals Inc | Dérivés monométhyle triterpénoïdes en c4 et leurs procédés d'utilisation |
CN103156861B (zh) * | 2011-12-08 | 2015-11-25 | 陈丽梅 | 齐敦果酸衍生物及其可药用盐在治疗糖尿病眼病中的应用 |
ME02926B (fr) | 2012-04-27 | 2018-04-20 | Reata Pharmaceuticals Inc | Dérivés 2,2-difluoropropionamide de bardoxolone méthyle, leurs formes polymorphes et leurs procédés d'utilisation |
US8921419B2 (en) | 2012-05-08 | 2014-12-30 | Trustees Of Dartmouth College | Triterpenoids and compositions containing the same |
US8981144B2 (en) | 2012-05-08 | 2015-03-17 | Trustees Of Dartmouth College | Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof |
WO2013188818A1 (fr) | 2012-06-15 | 2013-12-19 | Reata Pharmaceuticals, Inc. | Modulateurs anti-inflammation basés sur des triterpénoïdes époxydés au niveau du cycle a et leurs méthodes d'utilisation |
EP2892912B1 (fr) | 2012-09-10 | 2019-04-24 | Reata Pharmaceuticals, Inc. | Dérivés c17-alcanediylés et alcènediylés de l'acide oléanolique et leurs procédés d'utilisation |
US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
WO2014040073A1 (fr) | 2012-09-10 | 2014-03-13 | Reata Pharmaceuticals, Inc. | Dérivés c13-hydroxy de l'acide oléanolique et leurs procédés d'utilisation |
US20140073700A1 (en) * | 2012-09-10 | 2014-03-13 | Abbvie Inc. | Glycyrrhetinic acid derivatives and methods of use thereof |
WO2014048033A1 (fr) | 2012-09-28 | 2014-04-03 | Applied Pharmaceutical Science, Inc. | Polymorphes de l'ester éthylique cddo et leurs utilisations |
CN102875634B (zh) * | 2012-10-24 | 2014-08-20 | 苏州晶云药物科技有限公司 | 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型 |
CN102887936A (zh) * | 2012-10-24 | 2013-01-23 | 苏州晶云药物科技有限公司 | 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型 |
WO2014148455A1 (fr) | 2013-03-19 | 2014-09-25 | 第一三共株式会社 | Dérivé terpénoïde |
TW201936625A (zh) | 2013-04-24 | 2019-09-16 | 美商艾伯維有限公司 | 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法 |
BR112016003454B1 (pt) * | 2013-08-23 | 2023-02-14 | Reata Pharmaceuticals, Inc. | Uso de composto de metil bardoxolona |
WO2016033132A1 (fr) | 2014-08-26 | 2016-03-03 | Trustees Of Dartmouth College | Analogues pyridyles du 1-(2-cyano-3,12-dioxooléana-1,9(11)dièn-28-oyl)imidazole |
US10189791B2 (en) | 2014-08-26 | 2019-01-29 | Trustees Of Dartmouth College | Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole |
EP3192875B1 (fr) | 2014-09-10 | 2019-12-18 | Daiichi Sankyo Company, Limited | Composition pharmaceutique à libération prolongée destinée au traitement et à la prévention de maladies ophtalmiques |
WO2016089648A1 (fr) | 2014-12-01 | 2016-06-09 | Vtv Therapeutics Llc | Inhibiteurs de bach1 en combinaison avec des activateurs de nrf2 et compositions pharmaceutiques les contenant |
JP6746605B2 (ja) | 2014-12-19 | 2020-08-26 | ガイストリッヒ・ファルマ・アーゲーGeistlich Pharma Ag | オキサチアジン様化合物を作製する方法 |
US11591302B2 (en) | 2014-12-19 | 2023-02-28 | Geistlich Pharm A Ag | Processes for preparing oxathiazin-like compounds |
CA2974726C (fr) | 2015-02-12 | 2023-09-19 | Reata Pharmaceuticals, Inc. | Enones tricycliques d'imidazolyle comme modulateurs antioxydants de l'inflammation |
AU2016286548B2 (en) | 2015-07-02 | 2020-12-10 | Acerta Pharma B.V. | Solid forms and formulations of (S)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo(1,5-a)pyrazin-1-yl)-N-(pyridin-2-yl)benzamide |
ES2865163T3 (es) | 2015-09-23 | 2021-10-15 | Reata Pharmaceuticals Inc | Derivados de ácido oleanólico modificado en C4 para la inhibición de il-17 y otros usos |
MX2019005401A (es) | 2016-11-08 | 2019-08-05 | Reata Pharmaceuticals Inc | Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma. |
TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物 |
WO2019014412A1 (fr) | 2017-07-13 | 2019-01-17 | Pliva Hrvatska D.O.O. | Nouvelles formes polymorphes cristallines du bardoxolone méthyle |
US11708463B2 (en) | 2018-04-06 | 2023-07-25 | Capsugel Belgium Nv | Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)] |
EP3807265A1 (fr) | 2018-06-15 | 2021-04-21 | Reata Pharmaceuticals, Inc. | Composés pyrazole et imidazole pour l'inhibition de l'il-17 et du rorgamma |
EP3810141A1 (fr) | 2018-06-20 | 2021-04-28 | Reata Pharmaceuticals, Inc. | Agonistes inverses dépendant de la cystéine de récepteurs nucléaires ror-gamma/ror-gamma-t et procédés de traitement de maladies ou de troubles associés |
KR20210096162A (ko) | 2018-11-27 | 2021-08-04 | 쿄와 기린 가부시키가이샤 | 의약 조성물 |
EP4146226A1 (fr) | 2020-05-09 | 2023-03-15 | Reata Pharmaceuticals Holdings, LLC | Procédés de traitement de la covid-19 à l'aide de méthyle de barbarrolone ou d'analogues de celui-ci |
US12059419B2 (en) | 2020-10-16 | 2024-08-13 | Idience Co., Ltd. | Pharmaceutical composition comprising phthalazinone derivatives |
EP4259155A1 (fr) | 2020-12-11 | 2023-10-18 | Reata Pharmaceuticals Holdings, LLC | Triterpénoïdes synthétiques destinés à être utilisés en thérapie |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07121911B2 (ja) * | 1986-03-26 | 1995-12-25 | クミアイ化学工業株式会社 | 4(1h)−ピリジノン誘導体および農園芸用殺菌剤 |
JPH01273020A (ja) * | 1988-04-26 | 1989-10-31 | Toray Ind Inc | 有機非線形光学材料 |
US5064823A (en) * | 1988-08-24 | 1991-11-12 | Research Triangle Institute | Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers |
JP2876144B2 (ja) * | 1990-03-23 | 1999-03-31 | 東洋フアルマー株式会社 | 3―フェニルクマリン―7―イルオキシ酢酸誘導体とその製法及び用途 |
GB9622173D0 (en) * | 1996-10-24 | 1996-12-18 | Glaxo Group Ltd | Particulate Products |
US20050276836A1 (en) * | 1997-06-11 | 2005-12-15 | Michelle Wilson | Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents |
US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
US6890946B2 (en) * | 1999-12-23 | 2005-05-10 | Indiana University Research And Technology Corporation | Use of parthenolide to inhibit cancer |
US7435755B2 (en) * | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
CA2430454A1 (fr) * | 2000-11-28 | 2002-06-20 | Board Of Regents, The University Of Texas System | Composes cddo et polytherapies associees |
JP2006515859A (ja) * | 2002-05-13 | 2006-06-08 | トラスティーズ オブ ダートマス カレッジ | 阻害剤およびその使用法 |
JP3618341B2 (ja) * | 2003-04-15 | 2005-02-09 | 山之内製薬株式会社 | 臭化物及びその結晶 |
FR2861299B1 (fr) * | 2003-10-28 | 2006-01-27 | Pf Medicament | Compositions pharmaceutiques a base de derives d'idasoxan sous formes polymorphes |
US7652654B2 (en) | 2003-12-08 | 2010-01-26 | Sony Corporation | Liquid crystal display and backlight adjusting method |
US20060167097A1 (en) * | 2004-04-16 | 2006-07-27 | Cheppail Ramachandran | Compositions and uses of Amooranin compounds |
MX2007014782A (es) * | 2005-05-23 | 2008-02-19 | Novartis Ag | Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona. |
DE102005041613A1 (de) | 2005-09-01 | 2007-03-08 | Ergonex Pharma Gmbh | Pharmazeutische Zusammensetzungen zur Behandlung von Karzinoid-Syndrom |
JP5558719B2 (ja) | 2005-12-12 | 2014-07-23 | モサメディックス・ビー.ブイ. | 治療および診断におけるプレターゲッティングに適したアネキシン誘導体 |
US8088824B2 (en) * | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
-
2008
- 2008-08-13 US US12/191,176 patent/US8088824B2/en active Active
- 2008-08-14 LT LTEP12153605.6T patent/LT2450057T/lt unknown
- 2008-08-14 SI SI200831728A patent/SI2450057T1/sl unknown
- 2008-08-14 HU HUE12153605A patent/HUE031866T2/en unknown
- 2008-08-14 PL PL12153605T patent/PL2450057T3/pl unknown
- 2008-08-14 CL CL2008002417A patent/CL2008002417A1/es unknown
- 2008-08-14 CN CN2008801112346A patent/CN101820758B/zh active Active
- 2008-08-14 ES ES12153605.6T patent/ES2602978T3/es active Active
- 2008-08-14 ES ES08795303T patent/ES2382571T3/es active Active
- 2008-08-14 KR KR1020147002848A patent/KR101544766B1/ko active IP Right Grant
- 2008-08-14 SI SI200830650T patent/SI2187741T1/sl unknown
- 2008-08-14 AR ARP080103557A patent/AR073155A1/es unknown
- 2008-08-14 EP EP08795303A patent/EP2187741B1/fr active Active
- 2008-08-14 CA CA2871864A patent/CA2871864C/fr active Active
- 2008-08-14 WO PCT/US2008/009703 patent/WO2009023232A1/fr active Application Filing
- 2008-08-14 CA CA2696330A patent/CA2696330C/fr active Active
- 2008-08-14 DK DK08795303.0T patent/DK2187741T3/da active
- 2008-08-14 EA EA201370109A patent/EA023550B1/ru unknown
- 2008-08-14 EA EA201070149A patent/EA018704B1/ru unknown
- 2008-08-14 DK DK12153605.6T patent/DK2450057T3/en active
- 2008-08-14 TW TW102134576A patent/TWI486357B/zh active
- 2008-08-14 MX MX2010001628A patent/MX2010001628A/es active IP Right Grant
- 2008-08-14 TW TW097130947A patent/TWI419899B/zh active
- 2008-08-14 PT PT121536056T patent/PT2450057T/pt unknown
- 2008-08-14 KR KR1020107005094A patent/KR101481764B1/ko active IP Right Grant
- 2008-08-14 PT PT08795303T patent/PT2187741E/pt unknown
- 2008-08-14 AU AU2008287388A patent/AU2008287388B2/en active Active
- 2008-08-14 NZ NZ583269A patent/NZ583269A/en unknown
- 2008-08-14 CN CN201310016448.8A patent/CN103254267B/zh active Active
- 2008-08-14 JP JP2010521031A patent/JP5005812B2/ja active Active
- 2008-08-14 AT AT08795303T patent/ATE549035T1/de active
- 2008-08-14 PL PL08795303T patent/PL2187741T3/pl unknown
- 2008-08-14 BR BRPI0815540A patent/BRPI0815540A8/pt not_active Application Discontinuation
- 2008-08-14 SG SG2011094158A patent/SG177905A1/en unknown
- 2008-08-14 SG SG10201504650VA patent/SG10201504650VA/en unknown
- 2008-08-14 EP EP12153605.6A patent/EP2450057B1/fr active Active
-
2010
- 2010-02-09 IL IL203824A patent/IL203824A/en active IP Right Grant
- 2010-02-12 ZA ZA201001066A patent/ZA201001066B/xx unknown
- 2010-10-25 HK HK10110040.7A patent/HK1143537A1/xx unknown
-
2011
- 2011-11-29 US US13/306,043 patent/US8309601B2/en active Active
-
2012
- 2012-04-18 HR HRP20120350AT patent/HRP20120350T1/hr unknown
- 2012-05-23 JP JP2012117773A patent/JP2012188438A/ja active Pending
- 2012-06-13 CY CY20121100542T patent/CY1112864T1/el unknown
- 2012-06-29 US US13/537,583 patent/US8633243B2/en active Active
-
2015
- 2015-05-07 JP JP2015094538A patent/JP2015164939A/ja active Pending
-
2016
- 2016-11-15 HR HRP20161503TT patent/HRP20161503T1/hr unknown
- 2016-11-23 CY CY20161101205T patent/CY1118329T1/el unknown
-
2017
- 2017-03-27 IL IL251419A patent/IL251419A0/en unknown
- 2017-08-10 JP JP2017154939A patent/JP2018009001A/ja active Pending
-
2020
- 2020-03-25 AR ARP200100825A patent/AR119704A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20120350T1 (hr) | Novi oblici cddo metilnog estera | |
CN104968646B (zh) | Zeste同源物增强子2的抑制剂 | |
CN105980370B (zh) | 稠合的杂环化合物 | |
CA2953132C (fr) | Composes heteroaryle utiles en tant qu'inhibiteurs de l'enzyme d'activation sumo | |
CN103102344B (zh) | 氨基喹唑啉类衍生物及其盐和使用方法 | |
CN112823151A (zh) | 用于治疗与sting活性有关的疾病的化合物和组合物 | |
CN105143187A (zh) | 制备磺酰氯化合物的方法 | |
HRP20120007T1 (hr) | Polimorfni oblik 4-[3-(4-ciklopropankarbonil-piperazin-1-karbonil)-4-fluoro-benzil]-2h-ftalazin-1-ona | |
MX2010003927A (es) | Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b. | |
MA31571B1 (fr) | Composes organiques | |
CZ2012537A3 (cs) | Derivát kyseliny hyaluronové, způsob jeho přípravy, způsob jeho modifikace a použití | |
TW201431552A (zh) | 醫藥組成物 | |
IL202600A0 (en) | Azaindole-indole coupled derivatives, preparation methods and uses thereof | |
MX2009004467A (es) | Compuestos benzoilo amino heterociclilo como activadores de la glucoquinasa (glk). | |
WO2008024980A3 (fr) | Dérivés de pyrrole, de thiophène, de furane, d'imidazole, d'oxazole et de thiazole | |
TW201439085A (zh) | 單環吡啶衍生物 | |
Lu et al. | Synthesis and synergetic anti-tumor activity evaluation of dihydroartemisinin-organogermanium (IV) compound | |
TW202126622A (zh) | 用於治療與sting活性相關之病狀的化合物及組合物 | |
HRP20141172T1 (hr) | Disupstituirani spojevi tetrahidrofuranila kao antagonisti receptora bradikinina b1 | |
WO2009156837A3 (fr) | Forme amorphe d'un sel de malate de 2-indolinone à substitution 3-pyrrole | |
EA200700818A1 (ru) | Производные 1,2,4-триазолиламиноарил(гетероарил)сульфонамидов | |
JP6461088B2 (ja) | 高分子化カンプトテシン誘導体及び高分子化hsp90阻害剤誘導体を含む医薬組成物 | |
SI2601214T1 (en) | VEGF antagonist compositions and their use | |
CN103393604B (zh) | 枸橼酸他莫昔芬肠溶颗粒 | |
CN103142533B (zh) | 一种依托泊苷肠溶片 |